Key data
| Regulation | Royal Decree 710/2026, of September 2 |
|---|---|
| BOE Publication | September 3, 2026 |
| Entry into force | September 3, 2026 |
| Affected parties | Scientific and academic entities collaborating with AEMPS in public health |
| Category | Grants and Subsidies |
| Budget year | 2026 |
| Granting body | Ministry of Health (AEMPS) |
| Grant method | Direct award (without competitive bidding) |
| European co-financing | 80% European Commission (EU-JAMRAI 2 action) |
Specialized entities working with the Spanish Agency for Medicines and Health Products (AEMPS) receive direct financing from the Ministry of Health for 2026 without needing to compete in a competitive call. Royal Decree 710/2026, published on September 3, supports this expenditure from the Ministry of Health's budget for fiscal year 2026.
The justification for the direct method rests on three pillars: the public interest of the actions, the impossibility of comparing between entities due to the technical specificity of each one, and the need for operational continuity without interruptions in critical public health programs.
What does this regulation establish?
The Royal Decree regulates the direct award of grants in three differentiated areas of action. Below are the covered areas, identified beneficiaries, and funded actions:
| Area of action | Beneficiary | Description of action |
|---|---|---|
| Pharmacovigilance | Entities collaborating with AEMPS | Monitoring of adverse drug reactions |
| Antibiotic resistance (PRAN) | State Foundation for Health, Childhood and Social Welfare | Participation in the European joint action EU-JAMRAI 2, 80% co-financed by the European Commission; public awareness |
| National implant registries | Entities collaborating with AEMPS | Maintenance and control of registries of breast implants, pacemakers and defibrillators |
The regulation emphasizes that the direct award method is justified because the beneficiary entities are the only ones with the technical capacity and structure to execute these actions on a continuous basis. There is, therefore, no public call or possibility for other entities to compete for these grants in fiscal year 2026.
Economic and operational impact
The Royal Decree does not publish individual amounts per beneficiary in the available regulatory summary, but does establish that the expenditure is covered by the Ministry of Health's budget for 2026. The most relevant economic data is European co-financing:
This means that, in the case of the action linked to the National Plan against Antibiotic Resistance (PRAN), the Ministry of Health only finances the remaining 20% of the cost, with the European Commission being the main source of financing. This co-financing model reduces the impact on the national budget and aligns Spanish action with the European public health strategy.
From an operational perspective, direct award ensures the continuity of programs that cannot be interrupted: monitoring of adverse drug reactions, control of high-risk implantable devices (pacemakers, defibrillators, breast implants), and public awareness against inappropriate antibiotic use are activities with direct impact on patient safety.
Who does it affect?
- State Foundation for Health, Childhood and Social Welfare: direct beneficiary for the EU-JAMRAI 2 action within the framework of PRAN.
- Scientific and academic entities collaborating with AEMPS in pharmacovigilance matters.
- Entities managing national implant registries (breast implants, pacemakers and defibrillators).
- Ministry of Health: as the body that supports the expenditure and supervises execution.
- AEMPS: as the coordinating body of the subsidized actions.
This regulation does not affect private pharmaceutical companies or medical device manufacturers in terms of obligations or costs. Nor does it generate obligations for hospitals, clinics or healthcare professionals. Its scope is exclusively limited to already designated collaborating entities.
Practical example
The State Foundation for Health, Childhood and Social Welfare participates in the European joint action EU-JAMRAI 2, which is part of the European Union's strategy to combat antibiotic resistance. In this framework:
- The European Commission finances 80% of the total cost of the action.
- The Ministry of Health, through this Royal Decree, covers the remaining 20% from the 2026 budget.
- The Foundation executes public awareness activities and technical coordination within the framework of PRAN, without needing to compete in any competitive call.
This model ensures that Spain maintains its active participation in European public health initiatives without relying exclusively on the national budget, taking advantage of available community co-financing.
What should entities do now?
- Verify if your entity is designated as a beneficiary in Royal Decree 710/2026. Only entities expressly included can receive these direct grants.
- Review the justification requirements established in the Royal Decree for each area of action (pharmacovigilance, PRAN, implant registries).
- Coordinate with AEMPS the execution and justification timelines for expenditure corresponding to fiscal year 2026.
- For the EU-JAMRAI 2 action: ensure compliance with the European Commission's requirements as 80% co-financier, which may include monitoring reports and specific audits.
- If your entity is not included but carries out similar activities, this regulation does not open any access route for 2026. It is advisable to monitor future calls or regulatory changes for subsequent fiscal years.
Frequently asked questions
What entities receive direct grants from RD 710/2026?
The Royal Decree explicitly identifies the State Foundation for Health, Childhood and Social Welfare as a beneficiary for the EU-JAMRAI 2 action within the framework of PRAN. It also includes entities collaborating with AEMPS in pharmacovigilance and in the maintenance of national implant registries (breast implants, pacemakers and defibrillators).
Why are these grants awarded directly and not through a competitive process?
The regulation justifies the direct method for three reasons: the public interest of the actions, the impossibility of comparing between entities given their technical specificity, and the need for operational continuity without interruptions in critical public health programs.
How much does the European Commission finance in the action against antibiotic resistance?
The European Commission co-finances 80% of the cost of the EU-JAMRAI 2 joint action, in which the State Foundation for Health, Childhood and Social Welfare participates. The Ministry of Health covers the remaining 20% from the 2026 budget.
Can my entity apply for these grants if it is not included in the Royal Decree?
No. Direct award means there is no open call or possibility of competitive bidding for fiscal year 2026. Only entities expressly designated in Royal Decree 710/2026 can access these grants.
What medical devices are covered by the funded national implant registry?
The Royal Decree covers the maintenance of national registries of breast implants, pacemakers and defibrillators. These actions are aimed at ensuring traceability and safety of implants in Spain.
Official source
Consult complete regulation in official source
Notice: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2026-18512
